Standardization, analytical validation, and quality control of intermediate endpoint biomarkers

Area of Science:

• Oncology
• Biomarker Discovery
• Computational Pathology

Background:

• Standardized processes are essential for identifying and developing intermediate endpoint biomarkers (IEBs) to predict patient-specific disease outcomes.
• Current methods for biomarker development require refinement to ensure reliability and clinical utility.
• Prostate cancer diagnosis and prognosis can be significantly improved with novel, predictive biomarkers.

Purpose of the Study:

• To outline standardized processes for the development of intermediate endpoint biomarkers (IEBs).
• To introduce Quantitative Nuclear Grade (QNG), a novel biomarker for predicting prostate cancer outcomes.
• To demonstrate the clinical utility of new biomarkers and improved diagnostic strategies for prostate cancer.

Main Methods:

• Development of Quantitative Nuclear Grade (QNG) using computer-assisted image analysis of nuclear features from Feulgen-stained prostate tissue.
• Computation of QNG using logistic regression or artificial neural networks based on nuclear size, shape, and chromatin organization.
• Identification of novel prostate cancer genes using RNA fingerprinting and assessment of their clinical utility in blood and tissue samples.
• Enhancement of serum biomarker performance by combining prostate-specific antigen (PSA) molecular forms with new biomarkers.

Main Results:

• Quantitative Nuclear Grade (QNG) accurately predicted pathologic stage and progression of prostate cancer from biopsies (P <0.0001).
• QNG demonstrated high value in predicting postoperative biochemical progression in radical prostatectomy specimens with over 10 years of follow-up (P <0.0001).
• Novel, differentially expressed prostate cancer genes were identified, showing clinical utility in various sample types.

Conclusions:

• The development of new IEBs necessitates a deep understanding of disease molecular pathogenesis and standardized testing and validation methods.
• Quantitative Nuclear Grade (QNG) serves as an example of a highly predictive IEB for prostate cancer developed through standardized processes.
• Standardized IEB development and evaluation are critical for improving patient-specific disease outcome prediction and clinical decision-making in oncology.